A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)
ConditionHealthy
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age2-17
SponsorMerck Sharp & Dohme LLC
About this trial
The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue serotypes, regardless of dengue serostatus at baseline in children 2 to 17 years of age.
Eligibility criteria
Qualifiers
Is generally healthy based on medical history and physical examination.
Disqualifiers
Has a known or suspected impairment of immunological function.
Has a history of congenital or acquired immunodeficiency.
Has a documented human immunodeficiency virus (HIV) infection or is breastfeeding from a mother with documented HIV infection.
Has a documented history of hepatitis B or C infection.
Trial design
Treatments tested in this trial
- V181
- Placebo
Treatment groups
12,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov